The U.S. Food and Drug Administration today approved Erleada (apalutamide) for the treatment of patients with prostate cancer that has not spread (non-metastatic), but that continues to grow despite treatment with hormone therapy (castration-resistant). This is the first FDA-approved treatment for non-metastatic, castration-resistant prostate cancer. Continue reading.
jueves, 15 de febrero de 2018
Press Announcements > FDA approves new treatment for a certain type of prostate cancer using novel clinical trial endpoint
Press Announcements > FDA approves new treatment for a certain type of prostate cancer using novel clinical trial endpoint
![](https://blogger.googleusercontent.com/img/proxy/AVvXsEhmNymzf199_DVLtHiWvEg46OWOWnk_RaCwPfFFvl22zQLuukx9iwtkDpSn_u5AEyX41YlAKQqzJHeAYemhXe87qldBtEyCSqzNcgS-twkU_9cxw0avlOf49Lq8HzmTAB6ojGQlJFg5VNicAl4NX5VXxZs4NZvAMJLbo6eBC-2KH1_aIm-cpz-cRxv7gnNrNuiaDJGPANKhgPEe-pxAy2l892CK2JLRDx3oux5PiDsId1DYM219ifdC65Eq4N_gN2ZTXm2lPcdb0gWYoAg4fzk0Fj0154DmcA=s0-d-e1-ft)
The U.S. Food and Drug Administration today approved Erleada (apalutamide) for the treatment of patients with prostate cancer that has not spread (non-metastatic), but that continues to grow despite treatment with hormone therapy (castration-resistant). This is the first FDA-approved treatment for non-metastatic, castration-resistant prostate cancer. Continue reading.
The U.S. Food and Drug Administration today approved Erleada (apalutamide) for the treatment of patients with prostate cancer that has not spread (non-metastatic), but that continues to grow despite treatment with hormone therapy (castration-resistant). This is the first FDA-approved treatment for non-metastatic, castration-resistant prostate cancer. Continue reading.
Suscribirse a:
Enviar comentarios (Atom)
No hay comentarios:
Publicar un comentario